SpaceOAR System is an absorbable hydrogel spacer that is injected into the perirectal space between the prostate and rectum before radiotherapy for prostate cancer. After developing the final scope we determined that this topic was no longer suitable for medical technologies guidance. The topic will now be considered for selection by the technology appraisals programme.
- Status:
- In progress
- Decision:
- Selected
- Process:
- MTG
- ID number:
- 451
Project Team
- Project lead
- TBC
Email enquiries
If you have any queries please email [email protected]
Stakeholders
- External assessment group
- Newcastle Upon Tyne Hospitals
- Manufacturers
- Boston Scientific (Formerly Augmenix)
- Others
- Association of British Healthcare Industries (ABHI)
- Association of Healthcare Technology Providers for Imaging, Radiotherapy and Care (AXrEM)
- Boston Scientific
- Department of Health and Social Care
- Devices for Dignity
- Greater Manchester Health & Social Care Partnership
- Healthcare Improvement Scotland
- HealthTech Alliance
- Johnson & Johnson Medical Ltd
- Medical Technology Group
- Medicines and Healthcare Products Regulatory Agency
- NHS England
- The British In Vitro Diagnostics Association (BIVDA)
- Professional groups
- British Uro-Oncology Group
- Royal College of Radiologists
- Prostate Scotland
- The Society and College of Radiographers
- Intuitive
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 20 May 2019 | Scope published |
| 25 March 2019 | Stakeholder registration opens |
For further information on our processes and methods, please see our CHTE processes and methods manual